皂术茵陈方治疗非酒精性脂肪性肝炎40例临床研究

目的:观察皂术茵陈方治疗非酒精性脂肪性肝炎的临床疗效。方法:将78例患者单盲法随机分为治疗组40例和对照组38例;治疗组予中药皂术茵陈方治疗,对照组采用水飞蓟宾葡甲胺片(西利宾安)治疗;两组均治疗2个月。检测治疗前后患者血清谷丙转氨酶(AlT)、谷草转氨酶(AST)活性、血清总胆固醇(TCH)、甘油三酯(Tg)含量;比较患者肝脏b超变化以及症状、体征积分等临床疗效。结果:经过2个月治疗,治疗组的临床总有效率达87.50%,较之对照组的73.68%,差异有统计学意义(P<0.05);两组治疗后症状、体征积分、肝脏b超改善情况、血清AlT、AST活性、血清TCH、Tg含量均较各自治疗前显著改善;较之对照组,治疗组上述改善更加显著(P<0.05)。结论:中药皂术茵陈方对改善非酒精性脂肪性肝炎有较好的临床疗效,可明显改善患者肝功能、血脂、b超影像指标及临床证候。国家自然科学基金(No.81274155); 福建省卫生厅中医药项目(No.wzpw201408); 厦门市重大科技计划项目(No.3502Z20100006

慢性乙型肝炎患者肝组织HBcAg表达模式与中医证型的关系

目的:观察慢性乙型肝炎(CHB)患者肝组织乙型肝炎核心抗原(HBcAg)表达模式与中医证型及肝组织炎症、纤维化等指标的关系并进一步探讨相应的机制。方法:选择CHB患者556例,均进行中医辨证分型及肝组织活检,测定肝组织HBcAg表达模式、炎症、纤维化程度及ALT、AST、HBV DNA水平。结果:(1)556例患者按中医辨证标准分为6组:瘀血阻络证44例、肝肾阴虚证42例、肝郁气滞证48例、肝郁脾虚证282例、湿热蕴结证140例、脾肾阳虚证0例;按HBcAg表达模式分HBcAg阴性组42例、胞浆型HBcAg组186例、胞浆优势型HBcAg组290例、浆核各半型HBcAg组38例。(2)经Spearman秩相关分析,肝组织HBcAg表达模式与肝组织炎症活动度、纤维化程度均呈负相关;经Fisher确切概率检验,肝组织HBcAg表达模式与中医证型分布具有相关性。结论:肝组织HBcAg表达模式与中医证型、肝组织炎症、纤维化程度均有相关性;HBcAg阴性组、胞浆型HBcAg组及肝郁脾虚证、湿热蕴结证多处于慢性乙型肝炎活动期,正气未伤,免疫功能较强,为抗病毒治疗的较佳时机。国家自然科学基金项目(No.81503529,No.81673660);;福建省科技计划引导性项目(No.2015D007,No.2016D012);;厦门市科技惠民项目(No.3502Z20174028);;厦门市重要重大疾病联合攻关项目(No.3502Z20179047);;福建中医药大学基金项目(No.XB2016080)~

菖郁逍遥方治疗慢性乙型肝炎伴抑郁症的临床疗效及作用机制探讨

目的观察菖郁逍遥方治疗慢性乙型肝炎（chronic hepatitis B,CHB）伴抑郁症的临床疗效,并探讨其作用机制。方法 90例慢性CHB伴抑郁症患者,采用随机数字表法分为治疗组45例,对照组45例。在恩替卡韦治疗的基础上,对照组服用氟哌噻吨美利曲辛片;治疗组服用中药复方菖郁逍遥方,疗程12周。以汉密尔顿抑郁量表17项(Hamilton depression scale,HAMD17)评分观察治疗前、治疗中（治疗4周）、治疗后（治疗12周）两组患者的抑郁状态变化;以副反应量表（treatment emergent symptom scale,TESS）观察两组治疗后副反应;观察治疗前后血清ALT活性、乙型肝炎病毒DNA（hepatitis B virus DNA,HBV DNA）定量、5-羟色胺（5-hydroxytryptamine, 5-HT）、去甲肾腺上素（norepinephrine, NE）、脑源性神经营养因子（brain derived neurotrophic factor,BDNF）水平及内源性大麻素:N-花生四烯酸氨基乙醇（Arachidonoylethanolamine,AEA）、2-花生四烯酸甘油（2-arachidonoylglycerol,2-AG）及其受体（cannabinoid receptor,CBR）1、2指标变化。结果两组治疗中、治疗后的HAMD17评分较治疗前均明显降低（P0.05）。结论菖郁逍遥方具有显著改善CHB患者抑郁状态的临床疗效,作用机制与通过调控内源性大麻素水平来升高单胺类神经递质、BDNF相关。国家自然科学基金资助项目(No.81503529,No.81673660,No.81873242);;福建省科技计划引导性项目(No.2015D0007,No.2016D012);;厦门市科技计划项目(No.3502Z20174028);;厦门市重要重大疾病联合攻关项目(No.3502Z20179047);;福建省卫生计生医学创新科研人才培养项目(No.2018-CXB-28

Clinical Observation on Kangshi Kangxian Formula Combined with Interferon and Ribavirin in 33 Cases of Chronic Hepatitis C

目的观察康氏抗纤方联合聚乙二醇化干扰素α-2A(PEg-Ifnα-2A)、利巴韦林对慢性丙型肝炎(CHC)患者抗病毒治疗应答及生活质量的影响。方法选择CHC患者64例,随机分为治疗组33例与对照组31例。对照组给予PEg-Ifnα-2A注射液180μg/次,皮下注射,每周1次;利巴韦林0.3 g/次,口服,每天3次。治疗组在对照组基础上口服康氏抗纤方,每日1剂。两组均治疗24周。观察两组患者治疗前后肝组织病理、肝纤维化瞬时弹性测定值、血清丙氨酸氨基转氨酶(AlT)水平、丙肝病毒定量(HCV rnA)及慢性肝病问卷(CldQ)积分的变化。结果两组患者病毒学应答与生化应答比较差异无统计学意义(P>0.05)。治疗后两组肝脏炎症及纤维化程度均较本组治疗前显著改善(P 0.05).Inflammation and fibrosis of the liver were significantly improved after treatment( P < 0.05) compared within each group before.Improvement of liver fibrosis in treatment group is greater than control group( P < 0.05).On the improvement of Fibro Scan value,treatment group was obviously better than control group( P < 0.05).Every aspect of CLDQ scores of treatment group had different levels of increases( P < 0.01),while control group only had some increases on systemic symptom,activity ability and emotion scores( P < 0.05).After treatment,treatment group' s CLDQ scores on abdomenal pain,sleepinese,emotion and anxiety were notedly better than contreol group( P < 0.01).Conclusion Using Kangshi Kangxian Formula combined with PEG-IFNα-2a and ribavirin to treat CHC not only increased patient's response to antiviral therapy,but also improve the condition of liver fibrosis and patient's quality of life.福建省卫生厅青年科研课题基金资助项目(2012-2-105

Clinical Observation on Yixuesheng Capsule( 益血生胶囊) Combined with Western Medicine Treating 40 Cases of Chronic Viral Hepatitis C

目的观察益血生胶囊联合聚乙二醇化干扰素α-2A(PEg-Ifnα-2A)、利巴韦林片治疗慢性丙型病毒性肝炎的临床疗效。方法 80例慢性丙型病毒性肝炎患者采用随机数字表法分为治疗组和对照组各40例,均给予PEg-Ifnα-2A(每次180μg,皮下注射,每周1次)以及利巴韦林片(每次300 Mg,口服,每天3次)治疗,疗程6个月。治疗组在此治疗的首3个月,加用益血生胶囊口服,每次1 g,每天3次。两组患者治疗结束后随访6个月。观察治疗前后两组患者血清丙氨酸氨基转移酶水平、丙型肝炎病毒定量、中性粒细胞计数、血红蛋白含量、血小板计数的变化,比较两组患者生化学应答及病毒学应答百分比及骨髓抑制发生率。结果两组患者治疗3、6个月及随访6个月时病毒学应答比较差异均无统计学意义(P>0.05);两组患者治疗6个月及随访6个月生化学应答比较差异亦无统计学意义(P>0.05);治疗3、6个月时,治疗组的骨髓抑制发生率分别为35.00%及22.50%,均低于对照组的80.00%与60.00%(P 0.05).There was also no significant difference in biochemical responses between the two groups in the 6th month of treatment and the 6th month of following up( P > 0.05).In the 3rd and 6th month of treatment,the incidence of myelosuppression in treatment group was 35.00% and 22.50%,respectively,both of which were lower than that in control group( 80.00% and 60.00%,P < 0.01).Conclusion Combined with Yixuesheng Jiaonang,the effect of myelosuppression of PEG-IFNα2a and ribavirin treating CHC is attenuated,but the antiviral effect is not improved.福建省卫生厅青年科研课题(2012-2-105

Clinical Observation on 35 Cases of Chronic Hepatitis B Complicated with Depression Treated with Changyu Xiaoyao Fang( 菖郁逍遥方) Combined with Entecavir Dispersible Tablets

目的观察菖郁逍遥方联合恩替卡韦分散片治疗慢性乙型病毒性肝炎伴抑郁症的临床疗效及可能的作用机制。方法 67例慢性乙型病毒性肝炎伴抑郁症患者随机分为治疗组35例、对照组32例。在口服恩替卡韦分散片每日0.5 Mg的基础上,对照组加服氟哌噻吨美利曲辛片,每日2次,每次1片;治疗组加服中药复方菖郁逍遥方,每日1剂,两组疗程均为8周。治疗前后分别观察两组患者17项汉密尔顿抑郁量表(HAMd)、慢性肝病问卷(CldQ)积分以及血清白细胞介素6(Il-6)、肿瘤坏死因子α(Tnf-α)水平;比较两组患者抑郁状态疗效、血清丙氨酸氨基转移酶(AlT)复常率及乙型肝炎病毒dnA(HbV dnA)阴转率。结果治疗组抑郁状态疗效总有效率、AlT复常率、HbV dnA阴转率分别为80.00%、80.00%、60.00%,对照组分别为65.63%、62.50%、46.88%,治疗组均优于对照组(P<0.05)。与治疗前比较,治疗后两组患者HAMd评分、Il-6、Tnf-α水平均降低,CldQ各项得分及总积分均增加(P<0.05或P<0.01);治疗后治疗组Il-6、Tnf-α水平和CldQ各项得分及总积分改善程度较对照组更显著(P<0.05)。结论菖郁逍遥方联合恩替卡韦分散片可显著改善慢性乙型病毒性肝炎伴抑郁症患者的抑郁状态,并能增强抗病毒疗效、提高患者生活质量,其作用机制可能与抑制炎症反应相关。Objective To observe the clinical effect and possible mechanism of Changyu Xiaoyao Fang combined with entecavir dispersible tablets in treating chronic hepatitis B accompanied with depression.Methods67 patients with chronic hepatitis B accompanied with depression were randomly divided into a treatment group of 35 cases and a control group of 32 cases.In addition to taking 0.5 mg of entecavir dispersible tablet orally,control group was given flupentixol( 0.5 mg) and melitracen( 10 mg) tablet,one tablet twice a day orally,and treatment group was given Changyu Xiaoyao Fang one dose a day orally,both for 8 weeks.The scores of Hamilton Depression Scale( HAMD) and Chronic Liver Disease Questionnaire( CLDQ),as well as serum levels of interleukin 6( IL-6) and Tumor Necrosis Factorα( TNF-α) were detected before and after treatment.The improvement of depression,the normalization rate of serum level of alanine aminotransferase( ALT),and negative conversion rate of Hepatitis B Virus DNA( HBV DNA) in patients in both groups were observed after treatment.Results After treatment,the total effective rate in depression improvement,the normalization rate of ALT,and the negative conversion rate of HBV DNA was 80.0%,80.00% and 60.00%,respectively in treatment group,65.6%,62.50% and 46.88%,respectively in control group.The effects of all indexes in treatment group were superior to those in control group( P <0.05).The scores of HAMD,and levels of IL-6 and TNF-αwere decreased,and the scores of every items and total score of CLDQ were increased after treatment( P < 0.05 or P < 0.01).The improvement of IL-6,TNF-αand the scores of every items and total score of CLDQ in treatment group were superior to those in control group( P < 0.05).Conclusion Changyu Xiaoyao Fang combined with entecavir dispersible tablets could improve depression condition in patients with chronic hepatitis B accompanied with depression,strengthen antiviral effect,and improve quality of life.The mechanism may relate to inhibiting inflammation reaction.福建省卫生厅青年科研课题资助计划(2012-2-105); 福建省自然科学基金(2014J01374

Efficacy of CHSGS combined with interferon-αagainst chronic hepatitis B and effects on serum TNF-α,IL-6

目的：探讨柴胡疏肝散、甘草酸二铵肠溶胶囊对α-干扰素（interferon-alpha,IFN-α）治疗慢性乙型肝炎（chronic hepatitis B,CHB）疗效的观察及对肿瘤坏死因子-α（tumor necrosis factorα,TNF-α）、白细胞介素-6（interleukin-6,IL-6）水平的影响。方法：524例慢性乙型肝炎,按随机数字表法随机分为单药治疗组174例,联合中药治疗组174例,联合西药治疗组176例。单药治疗组采用IFN-α治疗24周;联合中药治疗组在IFN-α治疗基础上,采用柴胡疏肝散口服,每日1剂,疗程24周;联合西药治疗组在IFN-α治疗基础上,采用甘草酸二铵肠溶胶囊150-mg tid口服,疗程24周。观察3组治疗前后的症状积分改变情况、中医症状疗效、ALT水平、HBV DNA定量、抗病毒治疗应答及治疗前、治疗8周、治疗24周的TNF-α、IL-6水平的变化。结果：治疗24周后,联合中药治疗组症状积分改善程度最明显、中医症状疗效总有效率最高,联合西药治疗组次之,而单药治疗组最低（P0.05）。结论：INF-α联合柴胡疏肝散治疗慢性乙型肝炎可改善患者症状,增加INF-α抗病毒疗效,值得推荐联用,而联合甘草酸二铵肠溶胶囊治疗可降低INF-α抗病毒疗效,不推荐联合使用,INF-α及柴胡疏肝散均可以通过上调TNF-α、IL-6水平通过免疫激活来清除病毒,二者联用可起到协同作用。OBJECTIVE To explore the efficacy of Chaihu Shugan San（CHSGS）or diammonium glycyrrhizinate enteric-coated capsules combined with interferonα（interferonα,IFN-α）against chronic hepatitis B（CHB）.METHODS Totally 524 cases of CHB were randomly divided into 3 groups,including single drug group（174 cases）,traditional Chinese medicine（TCM）combined group（174 cases）and western medicine combined group（176 cases）.Patients were treated with IFN-αin single drug treatment group,with IFN-αbased on CHSGS in traditional Chinese medicine combined group,with IFN-αtreatment based on the licorice diammonium glycyrrhizinate enteric-coated capsules in western medicine combined group.The course of treatment was 24 weeks.Symptom score,the curative effect of TCM,ALT level,HBV DNA quantitation,antiviral treatment response were observed in three groups before and after treatment,changes of TNF-αand IL-6 levels were observed before treatment,after 8 weeks and 24 weeks of treatment.RESULTS After 24 weeks of treatment,the symptoms improved most obviously in TCM combined group and least in single drug group（P0.01,P0.05）.After treatment,the complete response rate was highest in TCM combined group and the lowest in single drug group（P0.05）.After 8 weeks of treatment,the levels of TNF-αand IL-6 were increased in TCM combined group and in single drug group but decreased in western medicine combined group,the levels of TNF-αand IL-6 were decreased in TCM combined treatment group and single drug group in8 and24 weeks of treatment.CONCLUSION IFN-αcombined with CHSGS or CHB can improve the symptoms of the patients,increase the antiviral efficacy,and it is worthy to be recommended.Combination with diammonium glycyrrhizinate enteric-coated capsules can reduce interferon antiviral efficacy,and should not be recommended.国家自然科学基金（No.81503529,NO.81673660）;福建省卫生厅中医药项目（No.wzpw201308）;福建省自然科学基金面上资助项目（No.2014J01374）;福建省科技计划引导性项目（No.2016D012）;厦门市科技计划项目（3502Z20134020

胸腺肽联合干扰素治疗慢性乙型肝炎临床疗效观察

厦门市科委资助项目!29880

EFFECTS OF THYMOSIN ON CONCENTRATIONS OF CYTOKINE IN SERUM OF PATIENTS WITH CHRONIC HEPATITIS B

目的观察大剂量国产胸腺肽对慢性活动性乙肝患者血清细胞因子的影响，探讨胸腺肽治疗慢性乙肝的机制。方法选择慢性活动性乙肝患者34例，分成两组：胸腺肽组19例，一般护肝组15例。比较观察治疗前后患者血清IFN—α、sIL－2r、TNF，和β2－MG为指标的变化。结果胸腺肽治疗后，患者PBMIFN—α诱生能力较治疗前上升119．99％，血清sIL—2r和TNF含量分别下降了35．56％和41．80％，治疗初期对β2—MG有提升作用。一般护肝组对慢性乙肝患者PBMIFN－α诱生能力和下调血清sIL-2r、TNF的作用弱于胸腺肽，对β2—MG指标没有影响。结论胸腺肽治疗慢性乙肝疗效与促进IFN产生和下调sIL-2r和TNF等多项免疫调节功能有关。Aim To dtudy the effects of high-dose thymosin on the cytokine conentration in serum of the patients with chronic hepatitis B and its therapy mechanism.Methods 34 patients with chronic active hepatitis B were divided into two groups; 19 patients were treated with thymosin and 15 patients with common drugs of protecting liver cells (PLC) .Level changes of IFN-α,sIL-2r, TNF, and β2-MG in the patients' serum were analyzed comparatively before and after treatment.Results After treating of thymosin, ability of induced-producing IFN-αin patients' PBMC was increased 119.99% over before treatment; concentrations of sIL-2r anu TNF in serum were decreased by 33.56% and 41.80%, respectively;and β2-MG in serum were increased in the early days of thymosin treatment.PLC showed similar, weaker effect on IFN-α, sII-2r, and TNF than that thymosin did; but no significant effects on β2-MG. Conclusions Mechanism of thymosin against HBV reproducing is relative to the the effets enhancing IFN-α producing abilities ,downing the serum levels of sIL-β2r and TNF,and so on.厦门市科委资助!Z9880